/PRNewswire/ Shanghai Henlius Biotech, Inc. (2696.HK) announced that the NDA for new indication of HANSIZHUANG, serplulimab, an innovative anti-PD-1 mAb.
SHANGHAI, Nov. 15, 2023 /PRNewswire/ Henlius（2696.HK）announced its financial results and business update for the first three quarters of 2023. As of September 30, 2023, Henlius generated a total revenue of RMB3.9278 billion, rising by 84.0% YoY, and a profit totaled RMB407.8 million, attributed to the highly efficient commercial operation and successive growth in core products. Among which, HANQUYOU.
Henlius Reported Financial Results For The First Three Quarters Of 2023: Total Revenue Exceeded RMB3 9 Billion, Profitability Further Improved menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
Intas Pharmaceuticals Ltd and Henlius Biotech enter into Exclusive License Agreement to commercialise serplulimab webindia123.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from webindia123.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Shanghai Henlius Biotech, Inc. (2696.HK) has entered into an exclusive license agreement with Intas Pharmaceuticals Limited ("Intas") for the.